GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

Discover a study that offers new insight into the link between frailty and steatotic liver disease in older adults.

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Simultaneous liver transplant and sleeve gastrectomy yield durable weight loss, resolution of diabetes and hypertension, and a reduction in allograft steatosis development.

Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.